CNS Pharmaceuticals Inc Ordinary Shares CNSP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
-
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
-
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
Trading Information
- Previous Close Price
- $5.78
- Day Range
- $5.75–5.79
- 52-Week Range
- $1.90–10.59
- Bid/Ask
- $5.75 / $6.00
- Shares Outstanding
- 1.46M
- Market Cap
- $8.40M
- Volume/Avg
- 1,579 / 10,464
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.cnspharma.com
Valuation
|
Metric
|
CNSP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.46 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CNSP
Financial Strength
|
Metric
|
CNSP
|
|---|---|
Quick Ratio | 5.35 |
Current Ratio | 5.86 |
Interest Coverage | −1,140.20 |
Quick Ratio
CNSP
Profitability
|
Metric
|
CNSP
|
|---|---|
Return on Assets (Normalized) | −134.68% |
Return on Equity (Normalized) | −181.01% |
Return on Invested Capital (Normalized) | −180.57% |
Return on Assets
CNSP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|wvvLm@w | LOCK|##&Lr | $130B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#@j#BD | LOCK|P^gD | $82B | |||
| argenx SE ADR
ARGX
| LOCK|^@c@#>< | LOCK|k? | $62B | |||
| Moderna Inc
MRNA
| LOCK|#mp>#l< | LOCK|$Kz | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&d@GX% | LOCK|DF@ | $40B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|WLZL!?% | LOCK|Fn^kl | $33B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|nx&jPLhm | LOCK|&<ST | $26B | |||
| Incyte Corp
INCY
| LOCK|fV@v?>$ | LOCK|VN | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|lFzJ$x | LOCK|N>n | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Wh!%%g | LOCK|L<B | $16B |
United States